Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 51st of 261 in Pharmacology & Pharmacy
  • 78th of 252 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.769
5 - Year: 3.923

Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects

Author(s): Anjana Bali, Nirmal Singh and Amteshwar Singh Jaggi

Affiliation: Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala-147002, Punjab, India.

Abstract

Stress has become an integral part of human life and organisms are being constantly subjected to stress and the ability to cope with such stress is a crucial determinant of health and disease. Neuropeptides (bioactive peptides) play a crucial role in mediating different effects of acute and chronic stress. Some of these neuropeptides including oxytocin, urocortins, neuropeptide Y (NPY), neuropeptide S, cocaine and amphetamine regulated transcript, endorphins, enkephalins, ghrelin and thyrotropin-releasing hormone primarily attenuate stress and act as anxiolytic. On the other hand, neuropeptides including corticotropin releasing hormone, vasopressin, dynorphin, angiotensin, nesfatin-1, orexin and cholecystokinin primarily tend to promote stress related anxiety behavior. However, these neuropeptide tend to produce different actions depending on the type of receptors, the nature and intensity of the stressor. For example, NPY may exhibit anxiolytic effects by activating NPY1 and Y5 receptors, while pro-depressive effects are produced through NPY2 and Y4 receptors. Galanin may produce ‘prodepressive’ effects by activating its Gal 1 receptors and exert ‘antidepressant’ effects through Gal 2 receptors. The present review describes different neuropeptides as therapeutic targets to attenuate stress-induced behavioral and neuroendocrinological effects.

Keywords: Stress, corticotropin releasing hormone, neuropeptide Y, orexins, oxytocin, vasopressin, opioids.

Purchase Online Rights and Permissions

Article Details

Volume: 13
Issue Number: 2
First Page: 347
Last Page: 368
Page Count: 22
DOI: 10.2174/1871527313666140314163920
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science